WHAT IS CLAIMED IS:

1. A compound of structural formula I:



(I)

or a pharmaceutically acceptable salt or solvate thereof, wherein

each n is independently 0, 1, or 2;

R^1 is hydrogen or C_{1-4} alkyl, wherein alkyl is unsubstituted or substituted with hydroxy or one to three fluorines;

R^2 is C_{1-4} alkyl, aryl, arylmethyl, heteroaryl, or heteroarylmethyl, wherein aryl and heteroaryl are unsubstituted or substituted with one to four R^6 substituents;

R^3 is hydrogen, halogen, or C_{1-4} alkyl, wherein alkyl is unsubstituted or substituted with hydroxy or one to three fluorines;

R^4 is hydrogen or C_{1-4} alkyl;

R^5 is $(CH_2)_n$aryl, $(CH_2)_nC_{4-9}$ cycloalkyl, $(CH_2)_nC_{5-11}$ bicycloalkyl, or $(CH_2)_nC_{10-14}$ tricycloalkyl; wherein said aryl, cycloalkyl, bicycloalkyl, and tricycloalkyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, trifluoromethyl, and C_{1-4} alkyl;

or R^4 and R^5 together with the nitrogen atom to which they are attached form a 5- to 7-membered ring saturated heterocycle optionally containing an additional heteroatom selected from O, S, and NC_{0-4} alkyl wherein said heterocycle optionally fused with a benzene ring and wherein said heterocycle or optionally benzo-fused heterocycle is unsubstituted or substituted with one to three substituents independently selected from halogen, C_{1-4} alkyl, trifluoromethyl, and $(CH_2)_n$aryl wherein aryl is unsubstituted or substituted with one to three substituents independently selected from halogen and C_{1-4} alkyl;

or R^4 and R^5 together with the nitrogen atom to which they are attached form a C_{6-11} azabicyclic ring system optionally containing an additional heteroatom selected from O, S, and NC_{0-4} alkyl said azabicyclic ring being unsubstituted or substituted with one to three substituents independntly selected from halogen, hydroxy, and C_{1-4} alkyl; and

each R^6 is independently selected from the group consisting of: amino, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino, halogen, cyano, C_{1-4} alkyl, hydroxy, C_{1-4} alkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfonyl, trifluoromethyl, trifluoromethoxy, aryl, and heteroaryl;

wherein aryl and heteroaryl are unsubstituted or substituted with one to three substituents independently selected from cyano, halogen, hydroxy, C_{1-4} alkoxy, C_{1-4} alkyl, trifluoromethyl, and trifluoromethoxy.

2. A compound of Claim 1 wherein R^1 is hydrogen.

3. A compound of Claim 2 wherein R^3 is hydrogen, halogen or methyl.

4. A compound of Claim 2 wherein R^2 is aryl or heteroaryl, wherein aryl and heteroaryl are unsubstituted or substituted with one to three R^6 substituents.

5. A compound of Claim 4 wherein R^2 is phenyl which is unsubstituted or substituted with one to three R^6 substituents.

6. The compound of Claim 1 wherein n is 0, R^4 is hydrogen or methyl and R^5 is C_{4-9} cycloalkyl, C_{5-11} bicycloalkyl or C_{10-14} tricycloalkyl; wherein said cycloalkyl, bicycloalkyl, and tricycloalkyl are unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, trifluoromethyl, and C_{1-4} alkyl.

7. A compound of Claim 6 wherein R^1 is methyl; R^2 is aryl or heteroaryl, wherein aryl and heteroaryl are unsubstituted or substituted with one to three R^6 substituents; and R^3 is hydrogen, methyl or chlorine.

8. A compound of Claim 1 wherein R^4 and R^5 together with the nitrogen atom to which they are attached form a 5- to 7-membered ring saturated heterocycle optionally containing an additional heteroatom selected from O, S, and NC_{0-4} alkyl wherein said heterocycle optionally fused with a benzene ring and wherein said heterocycle or optionally benzo-fused heterocycle is unsubstituted or substituted with one to three substituents independently selected from halogen, C_{1-4} alkyl, trifluoromethyl, and $(CH_2)_n$aryl wherein aryl is unsubstituted or substituted with one to three substituents independently selected from halogen and C_{1-4} alkyl.

9. The compound of Claim 8 wherein R^1 is methyl; R^2 is aryl or heteroaryl, wherein aryl and heteroaryl are unsubstituted or substituted with one to three R^6 substituents; and R^3 is hydrogen, methyl or chlorine.

10. The compound of Claim 1 wherein R^4 and R^5 together with the nitrogen atom to which they are attached form a C_{6-11} azabicyclic ring system optionally containing an additional heteroatom selected from O, S, and NC_{0-4} alkyl said azabicyclic ring being unsubstituted or substituted with one to three substituents independntly selected from halogen, hydroxy, and C_{1-4} alkyl.

11. The compound of Claim 10 wherein R^1 is methyl, R^2 is aryl or heteroaryl, wherein aryl and heteroaryl are unsubstituted or substituted with one to three R^6 substituents, and R^3 is hydrogen, methyl or chlorine.

12. The compound of Claim 1 wherein R^1 is methyl; R^2 is aryl or heteroaryl, wherein aryl and heteroaryl are unsubstituted or substituted with one to three R^6 substituents; R^3 is hydrogen, methyl or chlorine; R^4 is hydrogen; and R^5 is adamantyl or bicyclo[2.2.1]heptyl, unsubstituted or substituted with one to three substituents independently selected from methyl, hydroxy, and halogen.

13. A compound in accordance with claim 1 selected from the group consisting of:



	
	
and	

or a pharmaceutically acceptable salt or solvate thereof.

14. A compound in accordance with claim 1 selected from the following table:



(Ia)

Ex.	R^1	R^2	R^3	R^4
3	Me	2-F-phenyl	Cl	
4	Me	2-Br-phenyl	Me	
5	Me	2-Cl-phenyl	Me	

6	Me	2-Cl-phenyl	Cl	
7	Me	2-Cl-phenyl	Cl	
8	Me	2-Cl-phenyl	H	
9	Me	2-CF_3-phenyl	Me	
10	Me	3-OMe-phenyl	Me	
11	Me	2,4-di-F-phenyl	Me	
12	Me		Me	
13	Me	2-Me-phenyl	Me	
14	Me		Me	
15	Me	2-F-phenyl	Cl	
16	Me	4-OCF_3-phenyl	Cl	
17	Me	2-Cl-phenyl	Cl	
18	CH(CH3)2	4-Cl-phenyl	Me	
19	CH_2CF_3	4-Cl-phenyl	Me	
20	H	4-Cl-phenyl	Cl	
21	Me	Benzyl	Me	

or a pharmaceutically acceptable salt or solvate thereof.

15. A pharmaceutical composition comprising a compound in accordance with Claim 1 in combination with a pharmaceutically acceptable carrier.

16. A method of treating hyperglycemia, diabetes or insulin resistance in a mammalian patient in need of such treatment which comprises administering to said patient an effective amount of a compound in accordance with Claim 1.

17. A method of treating non-insulin dependent diabetes mellitus in a mammalian patient in need of such treatment comprising administering to the patient an anti-diabetic effective amount of a compound in accordance with Claim 1.

18. A method of treating obesity in a mammalian patient in need of such treatment compriseing administering to said patient a compound in accordance with Claim 1 in an amount that is effective to treat obesity.

19. A method of treating Syndrome X in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective to treat Syndrome X.

20. A method of treating a lipid disorder selected from the group conisting of dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective to treat said lipid disorder.

21. A method of treating atherosclerosis in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with Claim 1 in an amount effective to treat atherosclerosis.